Fn14 exacerbates acute lung injury by activating the NLRP3 inflammasome in mice

Xin-Xin Guan¹, Hui-Hui Yang¹, Wen-Jing Zhong¹, Jia-Xi Duan², Chen-Yu Zhang¹, Hui-Ling Jiang¹, Yang Xiang¹, Yong Zhou¹* and Cha-Xiang Guan¹*

Abstract

Background: Uncontrolled inflammation is an important factor in the occurrence and development of acute lung injury (ALI). Fibroblast growth factor-inducible 14 (Fn14), a plasma membrane-anchored receptor, takes part in the pathological process of a variety of acute and chronic inflammatory diseases. However, the role of Fn14 in ALI has not yet been elucidated. This study aimed to investigate whether the activation of Fn14 exacerbated lipopolysaccharide (LPS)-induced ALI in mice.

Methods: In vivo, ALI was induced by intratracheal LPS-challenge combined with/without Fn14 receptor blocker aurintricarboxylic acid (ATA) treatment in C57BL/6J mice. Following LPS administration, the survival rate, lung tissue injury, inflammatory cell infiltration, inflammatory factor secretion, oxidative stress, and NLRP3 inflammasome activation were assessed. In vitro, primary murine macrophages were used to evaluate the underlying mechanism by which Fn14 activated the NLRP3 inflammasome. Lentivirus was used to silence Fn14 to observe its effect on the activation of NLRP3 inflammasome in macrophages.

Results: In this study, we found that Fn14 expression was significantly increased in the lungs of LPS-induced ALI mice. The inhibition of Fn14 with ATA downregulated the protein expression of Fn14 in the lungs and improved the survival rate of mice receiving a lethal dose of LPS. ATA also attenuated lung tissue damage by decreasing the infiltration of macrophages and neutrophils, reducing inflammation, and suppressing oxidative stress. Importantly, we found that ATA strongly inhibited the activation of NLRP3 inflammasome in the lungs of ALI mice. Furthermore, in vitro, TWEAK, a natural ligand of Fn14, amplified the activation of NLRP3 inflammasome in the primary murine macrophage. By contrast, inhibition of Fn14 with shRNA decreased the expression of Fn14, NLRP3, Caspase-1 p10, and Caspase-1 p20, and the production of IL-1β and IL-18. Furthermore, the activation of Fn14 promoted the production of reactive oxygen species and inhibited the activation of Nrf2-HO-1 in activated macrophages.

Conclusions: Our study first reports that the activation of Fn14 aggravates ALI by amplifying the activation of NLRP3 inflammasome. Therefore, blocking Fn14 may be a potential way to treat ALI.

Keywords: Acute lung injury, Fn14, NLRP3 inflammasome, TWEAK, Macrophage

Introduction

Acute lung injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS), are the most common critical illnesses in clinical practice. ARDS is characterized by the development of uncontrolled pulmonary inflammation, disruptions of the alveolar-capillary barrier function, and non-cardiogenic pulmonary edema (Fan et al. 2018). Particularly, the infiltration of inflammatory
cells and increased pro-inflammatory cytokines and chemokines are the major pathological hallmarks of ALI. As the worldwide spread of SARS-CoV2, the research on the mechanism of ARDS is drawing more attention, as severe COVID-19 patients most end in ARDS (Xu et al. 2020). Despite multiple diverse therapeutic methods, only a few effective therapies are available to treat ALI. The mortality in critically ill patients remains at 40% (Matthay et al. 2019). Better understanding the molecular basis of ALI may explore new anti-inflammatory drugs.

The NLRs family, pyrin domain containing 3 (NLRP3) inflammasome, one of the pattern recognition receptors, plays a central role in the development of ALI (Zhang et al. 2016). The NLRP3 inflammasome is a multiprotein complex comprised of NLRP3, pro-caspase-1, and ASC. We have identified that inhibiting the activation of NLRP3 inflammasome alleviates LPS-induced ALI (Yang et al. 2020). The activation of NLRP3 inflammasome includes two steps: priming and activation. Toll-like receptors (TLR) mediate the priming of NLRP3 inflammasome through the nuclear factor-kB (NF-kB) pathway. Damage-related molecular patterns, such as adenosine triphosphate (ATP), mediate the activation of the NLRP3 inflammasome by inducing reactive oxygen species (ROS), ion flux (calcium ion influx or potassium ion outflow), or lysosomal detuning (Swanson et al. 2019). Moreover, the activation of NLRP3 inflammasome promotes the self-cleavage of Caspase-1 precursor into activated Caspase-1 (Caspase-1 p10 and Caspase-1 p20), then mediates the maturation and secretion of IL-1β and IL-18 (Pinar et al. 2020). We have reported that vasoactive intestinal peptides and epoxyeicosatrienoic acids attenuate LPS-induced ALI in mice by targeting the activation of NLRP3 inflammasome (Yang et al. 2020; Zhou et al. 2020; Luo et al. 2020). However, the mechanism underlying the activation of NLRP3 inflammasome in LPS-induced ALI mice needs to be investigated.

Fibroblast growth factor-inducible 14 (Fn14) is the receptor of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and belongs to the TNF receptor superfamily (Winkles 2008). Fn14 has a low level of ubiquitous expression on many cells. However, stress or inflammation could induce an increased expression. Fn14 is reportedly involved in acute and chronic inflammatory diseases, such as hepatitis, rheumatoid arthritis, and intestinal diseases (Affo et al. 2013; Kuijik et al. 2010; Martino et al. 2016). In addition, the increased expression of Fn14 in the lungs of sepsis patients correlates with tissue damage (Zou et al. 2018). However, whether Fn14 participates in ALI and its mechanism remains unclear. Fn14 activation could induce both the classical (canonical) pathway and the alternative (non-canonical) NF-kB signaling, leading to pro-inflammatory cytokines expression and contributing to tissue inflammation (Sanz et al. 2011). Interestingly, Fn14 promotes the maturation and secretion of IL-1β (Xu et al. 2017). Therefore, we assume that Fn14 participates in the cascade reaction of ALI, which may be related to NLRP3 inflammasome activation.

In this study, we investigated whether blocking Fn14 with an inhibitor (aurintricarboxylic acid, ATA) (Zhang et al. 2019) conferred protection against LPS-induced ALI. The study also could provide new insight into the mechanism underlying the activation of NLRP3 inflammasome in macrophages during ALI.

Materials and methods

Animal

Adult (6–8 weeks, 18–20 g) male C57BL/6J mice were purchased from Hunan SJA Laboratory Animal Co., Ltd (Hunan, China). All animal experiments were approved by the Animal Care and Use Committee at Central South University and strictly followed guidelines regarding the care of laboratory animals. All animal experiments were approved by the Ethics Committee of the School of Basic Medical Science, Central South University (2020sydw0685, Changsha, China).

ALI model and animal treatment

C57BL/6J mice were randomly divided into four groups: (a) the Control group, (b) the ATA group, (c) the ALI group, and (d) the ALI + ATA group. Mice in the Control and ATA groups received 50 µL sterile saline intratracheally. Mice in the ALI and ALI + ATA groups were given an intratracheal injection of LPS (E. coli O111:B4; Sigma-Aldrich; USA) at 5 mg/kg dissolved in 50 µL sterile saline. After intratracheal instillation, the mice were kept vertical for 5 min to ensure the distribution of the LPS or sterile in the lungs. In the ATA and ALI + ATA groups, ATA (20 mg/kg) was intraperitoneally injected 1 h prior to the LPS instillation. All mice were sacrificed 12 h after LPS instillation, and the lungs were collected and weighted. For the survival study, the mice were intratracheally injected with LPS at a lethal dose (25 mg/kg). Saline or ATA (20 mg/kg) was intraperitoneally injected into mice 1 h before or after LPS administration. The survival rate was monitored every 6 h. All surgical procedures were performed under 1.0% pentobarbital in saline (80 mg/kg).

Hematoxylin-eosin (HE) and inflammatory injury analysis

The lung tissue samples were collected, fixed in 10% formalin, embedded in paraffin, sectioned at 4 µm, and stained with HE. Histological scoring was performed blindly in line with four parts: alveolar congestion, hemorrhage, infiltration, and thickness of the alveolar wall/hyaline membrane formation. The lung injury score was...
measured as previously described (Duan et al. 2017). The severity of the injury was graded from 0 to 4 according to 5 variables: hyaline membranes, neutrophils in the alveolar space, hemorrhage, septal thickening, and pertinacious debris filling the airspaces.

**Lactate dehydrogenase (LDH) assay**
The activity of LDH in the serum of mice was determined by a Lactate Dehydrogenase Activity Assay Kit (Jincheng Bioengineering Institute, Nanjing, China). Briefly, the serum samples were incubated with NADH and pyruvate for 15 min at 37 °C. Then, the enzymatic reaction was stopped by 0.4 mol/L NaOH. Then, absorbance was measured at 450 nm.

**Bronchoalveolar lavage fluid (BALF)**
As previously described (Zhou et al. 2017), BALF was collected with 0.8 mL of ice-cold PBS. The BALF was centrifuged at 1500 rpm for 5 min. The pellet cells were resuspended in PBS, and the cell numbers were counted. Protein concentration in BALF, an indicator of alveolar-capillary permeability, was measured using a BCA kit (Thermo Fisher Scientific). The number of total cells, macrophages, and neutrophils were counted with a hemocytometer and Wright-Giemsa staining.

**Measurement of myeloperoxidase (MPO)**
The lung tissue was weighed and homogenized. Then, according to the manufacturer’s instructions, MPO activity in the lungs was measured by the MPO assay kit (Nanjing Jiancheng Bioengineering Institute, China).

**Measurement of superoxide dismutase (SOD) and malondialdehyde (MDA)**
About 40 mg of left upper lung tissue was homogenated in cold PBS at a ratio of 1:10 (weight: volume). Protein concentration was determined using the BCA kit. The MDA level was measured by the thiobarbituric acid (TBA) method using a lipid peroxidation MDA assay kit (Jincheng Biotech, Nanjing, Jiangsu, China) according to the manufacturer’s instructions. Absorbance at 530 nm was measured by the microplate reader. SOD activity was evaluated by the xanthine oxidase method using a SOD activity assay kit (Jincheng Biotech, Nanjing, Jiangsu, China) according to the manufacturer’s instructions. Absorbance was measured at 450 nm by the microplate reader.

**Measurements of cytokine levels in the lungs**
The contents of tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) in lung tissue, BALF, and cell culture supernatant were determined by specific enzyme-linked immunosorbent assay (ELISA) kits (Invitrogen; Thermo Fisher Scientific) according to the manufacturer’s instructions. The contents of interleukin-18 (IL-18) were determined by specific enzyme-linked immunosorbent assay (ELISA) kits (Jianglai Biotech, Shanghai, China) according to the manufacturer’s instructions.

**Real-time polymerase chain reaction (PCR)**
Total RNA was collected from lung tissue using RNAiso Plus (TaKaRa Clontech, Kusatsu, Japan) based on the manufacturer’s instructions. RNA was quantified by measuring absorption at 260 nm. The generation of cDNA from the total RNA (1 µg) was performed with Prime Script RT reagent Kit with gDNA eraser (TaKaRa). Real-time PCR was performed with SYBR Fast qPCR mix (TaKaRa) on a Bio-Rad real-time PCR system (CFX96 Touch, Bio-Rad, USA). β-actin was used as the internal control. The relative expressions (relative values) of the objective genes were calculated using the 2^−ΔΔCt method (Zhang et al. 2020). The sequence of primers used in this study is shown in Table 1.

**Western blot analysis**
Total protein was extracted from mouse lungs and cells by RIPA. Protein concentration was detected by the bicinchoninic acid assay (BCA, Thermo Fisher Scientific). Equal amounts of protein (30 µg) were loaded on SDS-PAGE and transferred to a polyvinylidene fluoride membrane (Zhou et al. 2016). After blocking with skim milk (5%) in Tris-buffered saline (TBST) for 1 h at room temperature, the membrane was probed with the primary antibodies at 4 °C overnight: rabbit anti-NLRP3 antibody (1:2000; CST, Danvers, MA), rabbit anti-NfκB antibody (1:1000, CST), rabbit anti-HO-1 antibody (1:1000, Abcam), goat anti-IL-1β antibody (1:2000; R&D, Minneapolis, MN), rabbit anti-caspase-1 antibody (1:1000; Abcam, Eugene, OR), rabbit anti-ASC antibody (1:1000, CST), rabbit anti-Fn14 antibody (1:1000, Abcam), rabbit anti-β-actin antibody (1:7500, Signal way Antibody, College Park, MD, USA), and rabbit anti-α-tubulin antibody (1:7500, Servicebio, China). After incubation with peroxidase-conjugated secondary antibodies (1:7500, Signal way Antibody) at room temperature for 1 h, the signal was developed using an ECL chemiluminescence kit (Millipore, USA). The band intensities were quantitated using Image Lab software and normalized to internal reference values accordingly.

**Isolation and treatment of primary murine peritoneal macrophages**
The isolation and culture of primary murine peritoneal macrophages were conducted as described (Zhong et al. 2019). Four days after the intraperitoneal injection of...
3 mL 3% thioglycolate (Sigma-Aldrich) into C57BL/6J mice, peritoneal macrophages were harvested by peritoneal lavage with precooled Roswell Park Memorial Institute RPMI 1640 (Gibco, Life Technologies, Carlsbad, CA). The cells were collected by centrifuging at 1000 rpm for 8 min and washed with cooled phosphate-buffered saline. The cells were resuspended in cell culture medium and counted on the counting plate after sufficient mixing. Macrophages were plated into 6-well or 12-well plates (2 × 10⁶ cells/well or 1 × 10⁶ cells/well). To investigate the effect of rTWEAK on the macrophages, the cells were treated with rTWEAK (100 ng/mL) and LPS (100 ng/mL) for 12 h. To investigate the activation of the NLRP3 inflammasome, the cells were primed with rTWEAK (100 ng/mL) and LPS (100 ng/mL) for 135 min. Cells were then stimulated with ATP (2.5 mM, Solarbio, China) for 45 min.

Measurement of ROS
The primary peritoneal macrophages (2 × 10⁶ cells/well) were seeded into the 6-well plates. Dilute DCFH-DA (Nanjing Jiancheng Bioengineering Institute, China) with RPMI 1640 at the ratio of 1:1000 to a final concentration of 10 µM. Add 1 mL diluted DCFH-DA solution to each well and incubate for 20 min at 37 °C. The cell suspension was obtained by adding 1 mL RPMI 1640, then centrifuged at 1500 rpm for 5 min, followed by resuspension with 400 µL PBS for flow cytometry assay (BD, USA).

Silenced the expression of Fn14 by shRNA
The short hairpin RNA (shRNA) of Fn14 was purchased from Genechem (Shanghai, China). Fn14 shRNA sequences were gattcggcttggtgttgatgc. Macrophages were infected with concentrated lentivirus. The supernatant was replaced with a complete culture medium after 16 h. After being treated with shRNA, the cells were primed with LPS (100 ng/mL) for 135 min. Cells were then stimulated with ATP (2.5 mM, Solarbio, China) for 45 min.

Statistical analysis
All experiments were independently repeated three times. All Data were presented as means ± SEM. All data analyses were conducted using SPSS 21. Pearson correlations were estimated to examine linear associations between the protein expression of Fn14 and the inflammation score, the protein expression of TNF-α, and the protein expression of IL-1β. Differences between the two groups were analyzed with a t-test. Differences between multiple groups were analyzed using ANOVA, followed by Tukey’s post hoc test. The survival rate was assayed by the log-rank test. A value of P < 0.05 was considered significant.

Results
Fn14 expression is increased in the lungs of ALI mice
We first investigated whether Fn14 expression was correlated with ALI. The mRNA and protein expression of Fn14 was raised in the lungs of LPS-induced ALI mice (Fig. 1A–C). These data suggest that Fn14 may be a key orchestrator in the pathogenesis of ALI.

Blockade of Fn14 by ATA alleviates LPS-induced lung injury in mice
ATA was previously identified as a novel inhibitor of Fn14 signaling (Zhang et al. 2019). Here, we adopted ATA to investigate the Fn14 function in ALI. The protein expression of Fn14 in the lungs of ALI mice was downregulated after pre-treatment with ATA (20 mg/kg) 1 h before LPS administration (Fig. 2A, B). Administration of ATA significantly reduced the mortality of mice receiving
25 mg/kg LPS (Fig. 2C). H&E staining indicated the accumulation of inflammatory cells, destruction of the alveolar histological structure, and the collapse of the alveoli in LPS-treated mice. Remarkably, ATA pre-treatment alleviated those pathological changes (Fig. 2D, E). The inflammation score was positively correlated with the Fn14 protein (Fig. 2F). LDH release is positively related to cellular damage. We found that ATA pre-treatment pronounced reduced the LDH activity in the serum (Fig. 2G). In parallel, the W/D ratio of lung tissue was...
significantly decreased in ATA-treated mice (Fig. 2H). ATA pre-treatment robustly reduced the number of total cells, macrophages, and neutrophils in the BALF (Fig. 2I–K) and MPO activity in the lungs (Fig. 2L), which reflects neutrophil accumulation in the lungs. Taken together, these data indicate that blockade of Fn14 mitigates lung damage in ALI mice.

**Blockade of Fn14 by ATA inhibits the inflammatory responses and oxidative stress in ALI mice**

Inflammation and oxidative stress are dispensable characteristics of ALI. We found that ATA pre-treatment reduced the pro-inflammatory cytokines and chemokines mRNA expression, including Tnf-α and Trem-1 (Fig. 3A, E). Protein expression of TNF-α in BALF and lungs was decreased in ATA-treated mice (Fig. 3B, C). TNF-α protein was positively correlated with Fn14 protein (Fig. 2D). MCP-1 recruits monocytes to the sites of inflammation. MCP-1 mRNA and protein expression were also down-regulated by ATA treatment (Fig. 3F, G). In addition, ATA pre-treatment reduced the MDA formation in the lungs of ALI mice (Fig. 3H). In contrast, ATA pre-treatment remarkably restored the activity of the antioxidative enzyme SOD in the lungs (Fig. 3I). Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a key transcription factor in the antioxidative stress response of cells. ATA pre-treatment remarkably increased the Nrf2 protein expression (Fig. 3J, K). Collectively, these results suggest that blockade of Fn14 inhibits inflammatory responses and oxidative stress in LPS-induced ALI mice.

**Blockade of Fn14 by ATA improves the survival of LPS-treated mice**

To explore the therapeutic potential of ATA, we investigated the potential benefits of ATA treatment (20 mg/kg) 2 h post-LPS administration. We found that treatment with ATA 2 h post-LPS exposure also significantly improved the survival rate of LPS-treated mice (Fig. 4). This result indicates that blockade of Fn14 shows therapeutic benefits to LPS-induced ALI mice.

**Blockade of Fn14 by ATA inhibits the NLRP3 inflammasome activation in ALI mice**

The NLRP3 inflammasome plays a vital role in the pathogenesis of ALI (Yang et al. 2020). We first investigated whether blockade of Fn14 with ATA repressed the activation of NLRP3 inflammasome in vivo. Results showed that ATA profoundly reduced the expression of Asc, Nlrp3, and pro-IL-1β mRNA in the lungs of ALI mice (Fig. 5A–C). Upon NLRP3 inflammasome activation, pro-caspase-1 is hydrolyzed into Caspase-1 p10 and Caspase-1 p20, cleaving pro-IL-1β into IL-1β. We found that ATA remarkably decreased the NLRP3, Caspase-1 p20, and Caspase-1 p10 protein levels in the lungs of ALI mice (Fig. 5D–G). NLRP3 inflammasome activation gives rise to the secretion of active IL-1β. The results showed that ATA pre-treatment effectively reduced the levels of IL-1β in BALF and lungs of ALI mice (Fig. 5H, I). IL-1β protein was positively correlated with Fn14 protein (Fig. 2J). These data suggest that the ATA inhibits the activation of NLRP3 inflammasome in the lungs of ALI mice.

**Activation of Fn14 by rTWEAK promotes the priming of NLRP3 inflammasome in macrophages**

Next, we investigated the effects of Fn14 on the NLRP3 inflammasome priming in primary macrophages. rTWEAK, a natural ligand of FN14, was used to stimulate primary peritoneal macrophages. Interestingly, we found that, compared with the LPS group, rTWEAK significantly increased the secretion of IL-1β but not TNF-α (Fig. 6A, B), indicating that rTWEAK specifically amplifies NLRP3 inflammasome-mediated inflammatory response. Further, we found that LPS induced the upregulations of NLRP3, pro-caspase-1, pro-IL-1β, and ASC expression. The rTWEAK treatment significantly increased the expressions of NLRP3, pro-caspase-1, pro-IL-1β, and ASC (Fig. 6C–G). These results suggest that activation of Fn14 promotes the priming of NLRP3 inflammasome.

**rTWEAK pre-treatment aggravates the activation of NLRP3 inflammasome in macrophages**

We treated macrophages with LPS plus ATP to activate the NLRP3 inflammasome. We found that pre-treatment of rTWEAK significantly increased the levels of Caspase-1 p10 and Caspase-1 p20 in macrophages treated by LPS with ATP (Fig. 7A–C). IL-1β p17 levels in the cells and supernatant increased upon rTWEAK treatment (Fig. 7D–G). IL-18 level in the supernatant was also increased upon rTWEAK stimulation (Fig. 7H). In addition, we silenced the expression of Fn14 in macrophages. Fn14 shRNA significantly decreased the Fn14 and NLRP3 expression induced by LPS and ATP (Fig. 8A–C). Furthermore, the level of Caspase-1 p10 and Caspase-1 p20 was effectively blocked by Fn14 shRNA in macrophages (Fig. 8D–F). IL-1β and IL-18 production were effectively blocked by Fn14 shRNA in macrophages (Fig. 8G, H). These data collectively suggest that activation of Fn14 by rTWEAK aggravates the activation of NLRP3 inflammasome in macrophages.

**rTWEAK pre-treatment promotes the ROS production and reduces the activation of Nrf2-HO-1 in macrophages**

Given that excessive ROS mediates NLRP3 inflammasome activation, we investigated whether activation of Fn14 could increase ROS production. As demonstrated
Fig. 3 Blockade of Fn14 by ATA reduces the inflammatory responses and oxidative stress in ALI mice. C57BL/6J mice were treated with saline or ATA (20 mg/kg). One hour later, mice were given saline or LPS (5 mg/kg, i.t.). A–C Twelve hours later, TNF-α mRNA and protein levels were determined by real-time PCR and ELISA (n=6–9). D The linear associations between the expression of Fn14 protein and TNF-α protein were analyzed with Pearson correlations analysis. E The expression of Trem-1 mRNA was determined by real-time PCR (n=5–7). F, G The MCP-1 mRNA and protein were determined by real-time PCR and ELISA (n=6–8). H The content of MDA in the lungs was determined (n=8). I The activity of SOD in lung tissue was determined (n=6–8). J, K The protein expression of Nrf2 in the lungs was determined by Western blot (n=3–4). Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pair-wise comparisons. *P<0.05, **P<0.01, and ***P<0.001.
Table 1 Sequences of specific primers used in this study

| Gene   | Forward primer (5’ to 3’) | Reverse primer (5’ to 3’) |
|--------|----------------------------|---------------------------|
| β-actin| CACCATGACCCAGGGCTATG       | CCGTCTTCGTGATCACCATC      |
| Mcp-1  | GCCCTGCTACTGCTTCTG         | GGTTAAGCTGACATGC          |
| Tnf-α  | CTAGGGGTCTCTTCTCTA         | TGTTTTGTGAGTAGGGT         |
| Pro-Il-1β| CAGGGACGGAGCATCACCTCA     | AGCTCATATGGGTCGACAG       |
| Trem-1 | CTGGCTGTTCTTGTTC           | CTTCGAGCTGTTAGGCT         |
| Asc    | GACAGTACCGAGAGGCTGCT       | AGGCTCTGACAGGAGGCTTC      |
| Nlrp3  | TACGCCGTCCTAGCTTCTCT      | CGCGACACACTCTCTCTCAA      |
| Fn14   | CAGATCTCGTTGGGATT         | AACATAGAAAACAGCCGCAA      |

Fig. 4 Therapeutic blockade of Fn14 by ATA improves the survival of LPS-treated mice. ATA (20 mg/kg) was administered to mice 2 h after induction of ALI by LPS (25 mg/kg). The mortality of the mice was monitored every 6 h over 96 h (n=20). Survival data were analyzed using the log-rank test. ***P<0.001

Discussion

In this study, we found blocking Fn14 reduced LPS-induced ALI in mice. Blockade of Fn14 suppressed the activation of NLRP3 inflammasome in vivo. In vitro, Fn14 activation amplified the activation of NLRP3 inflammasome in primary murine macrophages. Our study implies that Fn14 may play a key role in the pathogenesis of ALI and provides a novel mechanism of Fn14 activation on the inflammatory cascade.

This study identifies that elevated Fn14 is a novel mechanism in the uncontrolled inflammatory cascade during ALI. Fn14 is a type I transmembrane protein encoded by fibroblast growth factors-regulating early response gene (Mendez-Barbero et al. 2020). Studies have reported that Fn14 is significantly up-regulated in inflammation-related diseases, such as intestinal diseases and kidney disease, accelerating the course of illness (Dohi et al. 2009; Poveda et al. 2021). Our study found that Fn14 expression was significantly increased in LPS-induced ALI in mice. ATA is an inhibitor of Fn14, which blocks the TWEAK/Fn14 signal axis by inhibiting the binding of TRAF2 (Zhang et al. 2019). Herein, we found that ATA reduced lung tissue pathology injury, and decreased the number of inflammatory cells and pro-inflammatory cytokines such as TNF-α and MCP-1 in BALF. More importantly, the blockade of Fn14 activation effectively improved the survival rate of mice treated with a lethal dose of LPS. These results suggest that blocking Fn14 activation alleviates the LPS-induced ALI. In another study, blockade of Fn14 on pulmonary microvascular endothelial cells (PMVECs) shows a protective effect against cecal ligation and puncture-induced ALI (Zou et al. 2018). We speculated, therefore, that Fn14 may be a novel target for the treatment of ALI.

We reveal a new function of Fn14 in macrophages. Fn14 could express in different types of cells, such as macrophages, fibroblast (Zhang et al. 2021), PMVECs (Zou et al. 2018), vascular smooth muscle cells (Munoz-Garcia et al. 2011), and cancer cells (Dwyer et al. 2021). Previous studies have reported that Fn14 expressed on macrophages promotes oxidative stress through NADPH oxidase activation (Madrigal-Matute et al. 2015) or increases HMGB1 expression and secretion (Moreno et al. 2013). Herein, we found that Fn14 amplifies the...
Fig. 5 (See legend on previous page.)
activation of NLRP3 inflammasome in macrophages. Blocking Fn14 activation inhibited the expression of NLRP3, ASC, pro-caspase-1, pro-IL-1β, and secretion of IL-1β in LPS-induced ALI mice. The accumulation of evidence points to the central role of NLRP3 inflammasome in the ALI (Zhang et al. 2016; Liu et al. 2016). Interestingly, activation of Fn14 with rTWEAK fails to increase the TNF-α secretion, indicating that Fn14 specifically amplifies NLRP3 inflammasome-mediated inflammatory response. Therefore, we propose for the first time that activated Fn14 aggravates pulmonary inflammation by activating NLRP3 inflammasome, which may be a new mechanism explaining the uncontrolled inflammation in ALI.

Oxidative stress is the crucial pathogenesis of ALI. TWEAK-Fn14 axis is directly involved in oxidative stress. Our results indicate that ATA alleviates oxidative stress in the lungs of ALI mice and enhances the antioxidant capacity by up-regulating the expression of Nrf2 and SOD. It has been reported that excessive production of ROS induced by TWEAK could be eliminated by genetic silencing of Fn14 in macrophages (Madrigal-Matute et al. 2015). Furthermore, TWEAK/Fn14 could promote oxidative stress in the AMPK/PGC1-α-dependent manner (Liu et al. 2018). However, the underlying mechanism remains obscure.

Interestingly, there was no significant increase in TWEAK expression in the lungs of ALI mice (data not

**Fig. 6** Activation of Fn14 by rTWEAK promotes the priming of NLRP3 inflammasome in macrophages. rTWEAK (100 ng/mL) was added to LPS (100 ng/mL)-challenged primary macrophages for 12 h. A, B The contents of TNF-α and IL-1β in the supernatant of primary macrophages were determined (n = 3). C–G The expressions of NLRP3, pro-caspase-1, pro-IL-1β, and ASC protein in primary macrophages were determined by Western blot (n = 3). Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pair-wise comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001
Fig. 7  Pre-treated with rTWEAK aggravates the activation of NLRP3 inflammasome in macrophages. The cells were stimulated by rTWEAK (100 ng/ml) and LPS (100 ng/ml) for 135 min, and then ATP (2.5 mM) challenged primary macrophages for 45 min. A–C The levels of Caspase-1 p10 and Caspase-1 p20 in primary macrophages were determined by Western blot (n = 3). D, E The level of IL-1β p17 in primary macrophages was determined by Western blot (n = 3). F The level of IL-1β p17 in the supernatant of primary macrophages was determined by Western blot (n = 3). G The content of IL-1β p17 protein in the supernatant of primary macrophages was determined by ELISA (n = 3). H The content of IL-18 protein in the supernatant of primary macrophages was determined by ELISA (n = 3). Data are expressed as the mean ± SD. Differences among multiple groups were performed using ANOVA. Tukey’s test was used as a post hoc test to make pair-wise comparisons. *P < 0.05, **P < 0.01, and ***P < 0.001.
shown), indicating that Fn14 may execute its function independent of TWEAK, and there are other ligands for Fn14. Studies have also confirmed that the pro-inflammatory effect of TWEAK is mainly dependent on Fn14. The pro-inflammatory effect of TWEAK disappears after treatment with Fn14-siRNA (Sidler et al. 2017). While, Fn14 may interact with other mediators, mediating tissue inflammation. It has been reported that TWEAK was found to have no significant change in CCl4-induced acute liver injury (Wilhelm et al. 2016). While we observed that Fn14 expression was significantly up-regulated in ALI, indicating a pro-inflammatory role in the ALI process.

Fig. 8 The silence of Fn14 blocks the activation of NLRP3 inflammasome in macrophages. Fn14 shRNA was added before LPS (100 ng/mL)-challenged primary macrophages for 96 h. A–C The expressions of Fn14 and NLRP3 protein in primary macrophages were determined by Western blot (n = 3). D–F The levels of Caspase-1 p20 and p10 in primary macrophages were determined by Western blot (n = 3). G The contents of IL-1β in the supernatant of primary macrophages were determined (n = 3). H The contents of IL-18 in the supernatant of primary macrophages were determined (n = 3). Data are expressed as the mean ± SD. Differences between the two groups were determined by an unpaired t-test. *P < 0.05, **P < 0.01, and ***P < 0.001.
Conclusions

Our study indicates that the increased expression of Fn14 is a novel pathological mechanism in ALI. Blocking Fn14 effectively ameliorates LPS-induced ALI in mice. TWEAK/Fn14 axis activates the NLRP3 inflammasome, contributing to the uncontrolled inflammation response in ALI.

Abbreviations

ALI: Acute lung injury; ARDS: Acute respiratory distress syndrome; ATA: Aurintricarboxylic acid; ATP: Triphosphate; BALF: Bronchoalveolar lavage fluid; BCA: Bicinchoninic acid assay; ELISA: Enzyme-linked immunosorbent assay; Fn14: Fibroblast growth factor-inducible 14; HE: Hematoxylin-eosin; HO-1: Heme oxygenase-1; IL-1β: Interleukin-1 beta; LDH: Lactate dehydrogenase; LPS: Lipopolysaccharide; MCP-1: Monocyte chemotactic protein-1; MDA: Malondialdehyde; MPO: Myeloperoxidase; NLRP3: NLR family, pyrin domain containing 3; NF-κB: Nuclear factor-κB; Nrf2: Nuclear factor-erythroid 2-related factor 2; PCR: Real-time polymerase chain reaction; PMVECs: Pulmonary microvascular endothelial cells; ROS: Reactive oxygen species; SOD: Superoxide dismutase; TBA: Thiobarbituric acid; TLR: Toll-like receptors; TNF-α: Tumour necrosis factor alpha; TWEAK: Tumour necrosis factor-like weak inducer of apoptosis; TBST: Tris-buffered saline.

Acknowledgements

The authors would like to thank all the institutions and researchers who contributed to this study.


Author contributions

XGG, HYY, WJJ, CYZ, and HLJ performed the experiments; XGG, JDXX, and HYY analyzed the data; YZ, CGX, and YX contributed reagents/materials/analysis tools; XGG and WJJ wrote the paper; CGX and YZ conceived, designed the experiments, and critically reviewed the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (19149110, 82170096), the Open Project of the State Key Laboratory of Trauma, Burns, and Combined Injury, Army Medical University (SKLFK201702), High School Innovation Fund of Hunan province (19K103), and Fundamental Research Funds for the Central Universities of Central South University (2019zzts318).

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

All animal experiments were approved by the Ethics Committee of the School of Basic Medical Science, Central South University (2020sydw0685, Changsha, China).

Consent for publication

Not applicable.

Competing interests

The authors declared no conflict of interests.

Author details

1Department of Physiology, School of Basic Medical Science, Central South University, Changsha 410078, Hunan, China. 2Department of Pulmonary and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.

Received: 3 January 2022   Accepted: 20 July 2022
Published online: 30 July 2022

References

Affo S, Dornizuez M, Lozano­JS, Sancho­Brusco F, Brelje A, Morales­Iribarne O, Moreno M, Millan C, Ibañez del Castillo A, Altamirano J, Garcia­Pagan X, Arroyo V, Gines P, Caballeria J, Schwabe RE, Battaller R. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut. 2013;62:452–60.

Di Martino L, Dave M, Menghini P, Xin W, Arseneau KO, Pizarro TT, Cominelli F. Dwyer BJ, Jarman EJ, Gogoi­Tiwari J, Ferreira­Gonzalez S, Boulter L, Guest Affo S, Dominguez M, Lozano JJ, Sancho­Bru P, Rodrigo­Torres D, Morales­Garcia­Pagan JC, Arroyo V, Gines P, Caballeria J, Schwabe RF, Bataller R. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut. 2013;62:452–60.

Dobrucki T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, Runkel L, Rajman L, Dong X, Scott ML, Michaelson JS, Jakubowski A, Burkly LC. TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis. Gastroenterology. 2009;136:912–23.

Duan RX, Zhou Y, Zhou Y, Guan XX, Liu T, Yang HH, Xie H, Chen P. Calcitonin gene-related peptide exerts anti-inflammatory property through regulating murine macrophages polarization in vitro. Mol Immunol. 2017;131:103–13.

Dwyer BJ, Jarman EJ, Gogoi­Tiwari J, Ferreira­Gonzalez S, Boulter L, Guest RV, Kendall TJ, Kuriyan D, Kilpatrick AM, Robson AJ, ODubhain E, Man TY, Campana L, Lewis S, Wigmore PJ, Olynky SJ, Ramm JK, Tirin­zarka­Gar, Forbes SJ. TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression. J Hepatol. 2021;74:860–872.

Fan E, Brodie D, Slusky AS. Acute respiratory distress syndrome: advances in diagnosis and treatment. JAMA. 2018;319:698–710.

Liu T, Zhou Y, Li P, Duan JX, Liu YP, Sun GY, Wan L, Dong L, Fang X, Jiang JX, Guan CX. Blocking triggering receptor expressed on myeloid cells-1 attenuates lipopolysaccharide-induced acute lung injury via inhibiting NLRP3 inflammasome activation. Sci Rep. 2016;6:39473.

Liu H, Peng H, Xiang H, Guo L, Chen R, Zhao S, Chen W, Chen P, Lu H, Chen S. TWEAK/Fn14 promotes oxidative stress through AMPK/PGC1al‑pha/MnSOD signaling pathway in endothelial cells. Mol Med Rep. 2018;17:1998–2004.

Luo XQ, Duan JX, Yang HH, Zhang CY, Sun CC, Guan XX, Xiong JB, Zu C, Tao JH, Zhou Y, Guan CX. Epoxideisocetaric acids inhibit the activation of NLRP3 inflammasome in murine macrophages. J Cell Physiol. 2020;235:9910–21.

Madrigal­Matute J, Fernandez­Laso V, Sastre C, Llamas­Granda P, Egido J, Martin­Ventura JL, Zalfa G, Blanco­Collo LM. TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res. 2015;108:139–47.

Matthy­MA, Zemans RL, Zimmerman GA, Arabi YM, Beutler JR, Mercat A, Her­ridge M, Randolph AG, Calfe CS. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5:18.

Mendez­Barbero N, Yuste­Montalvo A, Nunez­Borde E, Jensen BM, Gutierrez­Munoz C, Tome­Arnmat J, Garrido­Arandia M, Diaz­Perales A, Ballesteros­Martinez C, Laguna JJ, Beita JM, Poulsen LC, Cuesta­Herranz J, Blanco­Collo LM, Esteban V. The TNF-like weak inducer of the apoptosis/ fibroblast growth factor-inducible molecule 14 axis mediates histamine and platelet-activating factor-induced subcutaneous vascular leakage and an anaphylactic shock. J Allergy Clin Immunol. 2020;145:583–96.

Moreno JA, Sastre C, Madrigal­Matute J, Munoz­Garcia B, Ortega L, Burkly LC, Egido J, Martin­Ventura JL, Blanco­Collo LM. HMGB1 expression and secretion are increased via TWEAK/Fn14 interaction in atheroscle­rotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol. 2013;33:612–20.

Munoz­Garcia B, Madrigal­Matute J, Moreno JA, Martin­Ventura JL, Lopez­Franco O, Sastre C, Ortega L, Burkly LC, Egido J, Blanco­Collo LM. TWEAK/Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res. 2011;89:225–33.

Pina AA, Scott TE, Huuskes BM, Caceres T, Kemp­Harper FE, B. K. & Samuel CS. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacol Ther. 2020;209:107511.

Poveda J, Vazquez­Sanchez S, Sanz AB, Ortiz A, Rulope LM, Ruiz­Hurtado G. TWEAK/Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome. J Pathol. 2021;254(1):5–19.

Sanz AB, Sanchez­Nino MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney Int. 2011;80:708–18.

Sidler D, Wu P, Herro R, Claus M, Wolf D, Kawakami Y, Kawakami T, Burkly LC, Croft M. TWEAK mediates inflammation in experimental aortic dermatitis and psoriasis. Nat Commun. 2017;8:15395.

Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nat Rev Immunol. 2019;19:477–89.

van Kuijk AJ, Wijbrandts CA, Vinkenoog M, Zheng TS, Reedquist KA, Tak PP. TWEAK and its receptor Fn14 in the synovium of patients with rheuma­toid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade. Ann Rheum Dis. 2010;69:301–9.

Wilkens A, Shephard EL, Amatucci A, Munir M, Reynolds G, Humphreys E, Resheq Y, Adams DH, Hubisher S, Burkly LC, Weston CJ, Afford SC. Interaction of TWEAK with Fn14 leads to the progression of fibrotic liver disease by directly modulating hepatic stellate cell proliferation. J Pathol. 2016;239:109–21.

Winkle J. The TWEAK/Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008;7:411–25.

Xu J, He J, He H, Peng R, Xi J. TWEAK/Fn14 Influences Neurogenesis Status via Modulating NF-kappaB in Mice with Spinal Cord Injury. Mol Neurobiol. 2017;54:7479–506.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia R, Dong J, Zhao J, Wang FS. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.

Yang HH, Duan JX, Liu SK, Xiong JB, Guan XX, Zhong WJ, Sun CC, Zhang CY, Luo XQ, Zhang YF, Chen P, Hammock BD, Hwang SH, Jiang XJ, Zhou Y, Guan CX. A COX-2/6E12 dual inhibitor PTP1B alleviates lipopolysaccha­ride-induced acute lung injury in mice by inhibiting NLRP3 inflamma­some activation. Theranostics. 2020;10:4749–61.
Zhang Y, Li X, Grailer JJ, Wang N, Wang M, Yao J, Zhong R, Gao GF, Ward PA, Tan DX, Li X. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res. 2016;60:405–14.
Zhang J, Dong B, Hao J, Yi S, Cai W, Luo Z. LncRNA Snhg3 contributes to dys-function of cerebral microvascular cells in intracerebral hemorrhage rats by activating the TWEAK/Fn14/STAT3 pathway. Life Sci. 2019;237:116929.
Zhang CY, Duan JX, Yang HH, Sun CC, Zhong WJ, Tao JH, Guan XX, Jiang HL, Hammock BD, Hwang SH, Zhou Y, Guan CX. COX-2/SEH dual inhibitor PTUPB alleviates bleomycin-induced pulmonary fibrosis in mice via inhibiting senescence. FEBS J. 2020;287:1666–80.
Zhang Y, Zeng W, Xia Y. TWEAK/Fn14 axis is an important player in fibrosis. J Cell Physiol. 2021;236:3304–16.
Zhong WJ, Yang HH, Guan XX, Xiong JB, Sun CC, Zhang CY, Luo XQ, Zhang YF, Zhang J, Duan JX, Zhou Y, Guan CX. Inhibition of glycolysis alleviates lipopolysaccharide-induced acute lung injury in a mouse model. J Cell Physiol. 2019;234:4641–45.
Zhou Y, Yang J, Sun GY, Liu T, Duan JX, Zhou HF, Lee KS, Hammock BD, Fang X, Jiang JX, Guan CX. Soluble epoxide hydrolase inhibitor 1-trifluoromethyl-oxophenyl-1,3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice. Cell Tissue Res. 2016;363:399–409.
Zhou Y, Liu T, Duan JX, Li P, Sun GY, Liu YP, Zhang J, Dong L, Lee KSS, Hammock BD, Jiang JX, Guan CX. Soluble epoxide hydrolase inhibitor attenuates lipopolysaccharide-induced acute lung injury and improves survival in mice. Shock. 2017;47:638–45.
Zhou Y, Zhang CY, Duan JX, Li Q, Yang HH, Sun CC, Zhang J, Luo XQ, Liu SK. Vasoactive intestinal peptide suppresses the NLRP3 inflammasome activation in lipopolysaccharide-induced acute lung injury mice and macrophages. Biomed Pharmacother. 2020;121:109596.
Zou Y, Bao S, Wang F, Guo L, Zhu J, Wang J, Deng X, Li J. FN14 blockade on pulmonary microvascular endothelial cells improves the outcome of sepsis-induced acute lung injury. Shock. 2018;49:213–20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.